Analysts Set Stryker Corporation (SYK) Price Target at $150.26

Shares of Stryker Corporation (NYSE:SYK) have been assigned an average recommendation of “Hold” from the twenty-five brokerages that are covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, ten have assigned a hold recommendation and twelve have issued a buy recommendation on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $151.47.

Several equities analysts have commented on the company. Needham & Company LLC reiterated a “hold” rating on shares of Stryker in a report on Thursday, December 7th. Royal Bank of Canada reiterated a “buy” rating and set a $155.00 price target on shares of Stryker in a report on Monday, October 2nd. BidaskClub upgraded Stryker from a “hold” rating to a “buy” rating in a report on Thursday, August 17th. BMO Capital Markets upgraded Stryker to a “market perform” rating and set a $163.00 price target on the stock in a report on Tuesday. Finally, SunTrust Banks reiterated a “buy” rating and set a $161.00 price target on shares of Stryker in a report on Monday, October 2nd.

In other news, insider Lonny J. Carpenter sold 5,000 shares of the firm’s stock in a transaction on Friday, November 3rd. The shares were sold at an average price of $155.34, for a total value of $776,700.00. Following the sale, the insider now owns 83,207 shares in the company, valued at $12,925,375.38. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 7.40% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of SYK. Koch Industries Inc. boosted its stake in Stryker by 34,120.3% during the second quarter. Koch Industries Inc. now owns 1,260,675 shares of the medical technology company’s stock worth $1,252,000 after buying an additional 1,256,991 shares in the last quarter. BlackRock Inc. boosted its stake in Stryker by 5.2% during the second quarter. BlackRock Inc. now owns 23,115,853 shares of the medical technology company’s stock worth $3,208,017,000 after buying an additional 1,139,082 shares in the last quarter. Janus Henderson Group PLC boosted its stake in Stryker by 2,237.8% during the second quarter. Janus Henderson Group PLC now owns 1,019,254 shares of the medical technology company’s stock worth $141,452,000 after buying an additional 975,656 shares in the last quarter. Vanguard Group Inc. boosted its stake in Stryker by 2.8% during the second quarter. Vanguard Group Inc. now owns 24,078,709 shares of the medical technology company’s stock worth $3,341,643,000 after buying an additional 657,656 shares in the last quarter. Finally, APG Asset Management N.V. boosted its stake in Stryker by 117.1% during the third quarter. APG Asset Management N.V. now owns 583,736 shares of the medical technology company’s stock worth $82,902,000 after buying an additional 314,800 shares in the last quarter. Hedge funds and other institutional investors own 74.97% of the company’s stock.

Shares of Stryker (SYK) traded down $1.97 during mid-day trading on Monday, reaching $151.34. The company’s stock had a trading volume of 1,406,741 shares, compared to its average volume of 1,178,710. Stryker has a one year low of $116.50 and a one year high of $160.62. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.61 and a current ratio of 2.37. The firm has a market capitalization of $57,509.09, a P/E ratio of 24.35, a PEG ratio of 2.42 and a beta of 0.78.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, October 26th. The medical technology company reported $1.52 EPS for the quarter, beating the consensus estimate of $1.50 by $0.02. Stryker had a return on equity of 24.11% and a net margin of 14.67%. The company had revenue of $3.01 billion for the quarter, compared to the consensus estimate of $2.97 billion. During the same quarter last year, the company posted $1.39 earnings per share. The company’s revenue for the quarter was up 6.1% compared to the same quarter last year. sell-side analysts expect that Stryker will post 6.47 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 31st. Stockholders of record on Friday, December 29th will be paid a $0.47 dividend. This is an increase from Stryker’s previous quarterly dividend of $0.43. The ex-dividend date of this dividend is Thursday, December 28th. This represents a $1.88 annualized dividend and a dividend yield of 1.24%. Stryker’s dividend payout ratio (DPR) is presently 36.32%.

WARNING: “Analysts Set Stryker Corporation (SYK) Price Target at $150.26” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.dispatchtribunal.com/2017/12/15/analysts-set-stryker-corporation-syk-price-target-at-150-26.html.

About Stryker

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Analyst Recommendations for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply